Remote Electrical Stimulation as a Long-term Intervention for Endometriosis Flare Ups

Description

The goal of this clinical trial is to learn if a wearable brain stimulation device called NettleEndo can reduce chronic pelvic pain and improve wellbeing in women with endometriosis. The study also aims to assess the safety and usability of the device when used at home over several months. The main questions it aims to answer are: 1. Does at-home transcranial direct current stimulation (tDCS) reduce daily pain intensity in women with endometriosis? 2. Does the device also improve mood and sleep quality? Researchers will compare two groups-one receiving active brain stimulation and one receiving a sham (placebo) stimulation-to see if the active device provides greater improvements in symptoms. Participants will: 1. Use the NettleEndo device at home for 20 minutes per session, five times per week for 12 weeks 2. Be randomly assigned to receive either real or sham stimulation through the device 3. Complete daily and weekly symptom ratings through a mobile app 4. Wear an optional fitness tracker to collect data on sleep, movement, and heart rate variability 5. Be followed for 60 days after completing the intervention to monitor longer-term effects All activities are completed remotely using a smartphone app. Participants can contact the study team with questions at any time. The study is double-blind, meaning neither participants nor the researchers assessing outcomes will know who received active or sham treatment until the end of the trial.

Conditions

Endometriosis

Talk to us

Study Overview

On this page

Study Details

Study overview

The goal of this clinical trial is to learn if a wearable brain stimulation device called NettleEndo can reduce chronic pelvic pain and improve wellbeing in women with endometriosis. The study also aims to assess the safety and usability of the device when used at home over several months. The main questions it aims to answer are: 1. Does at-home transcranial direct current stimulation (tDCS) reduce daily pain intensity in women with endometriosis? 2. Does the device also improve mood and sleep quality? Researchers will compare two groups-one receiving active brain stimulation and one receiving a sham (placebo) stimulation-to see if the active device provides greater improvements in symptoms. Participants will: 1. Use the NettleEndo device at home for 20 minutes per session, five times per week for 12 weeks 2. Be randomly assigned to receive either real or sham stimulation through the device 3. Complete daily and weekly symptom ratings through a mobile app 4. Wear an optional fitness tracker to collect data on sleep, movement, and heart rate variability 5. Be followed for 60 days after completing the intervention to monitor longer-term effects All activities are completed remotely using a smartphone app. Participants can contact the study team with questions at any time. The study is double-blind, meaning neither participants nor the researchers assessing outcomes will know who received active or sham treatment until the end of the trial.

At-Home Transcranial Direct Current Stimulation (tDCS) Using the NettleEndo Device for Reducing Symptoms of Endometriosis - A Phase II Double-Blind, Randomized, Placebo-Controlled Clinical Trial

Remote Electrical Stimulation as a Long-term Intervention for Endometriosis Flare Ups

Condition
Endometriosis
Intervention / Treatment

-

Contacts and Locations

San Francisco

Alethios, Inc., San Francisco, California, United States, 94109

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Female, 22-45 years old
  • * Assigned female at birth
  • * Fluent in English
  • * Capacity to consent
  • * Confirmed diagnosis of endometriosis by a qualified physician, via:
  • 1. Laparoscopic surgery with biopsy-proven endometriosis, OR
  • 2. Clear evidence of ovarian endometrioma or deep infiltrating endometriosis on ultrasound/MRI
  • * Mean NMPP NRS (non-menstrual pelvic pain) ≥ 2.5 OR ≥1.25 and ≥5 on at least 4 days (self-report)
  • * DYS NRS (dysmenorrhea-related pelvic pain) ≥4 on ≥2 days (self-report)
  • * Access to a smartphone with an internet data plan, phone must be iOS 13.4+, or Android 12+.
  • * No hormonal contraception or at least 6 months of consistent adherence to any hormonal contraception (e.g., IUD, pill, injection)
  • * Regular menstrual cycles (24-35 days) for the past six months
  • * Pregnancy/breastfeeding or planning to become pregnant in next 6 months
  • * History of epileptic neurological conditions in the immediate family
  • * Severe/untreated neurological disease (e.g., epilepsy or seizure disorders, stroke or transient ischemic attack \[TIA\], subarachnoid hemorrhage, traumatic brain injury \[TBI\] with persistent neurological deficits, brain tumors \[malignant or benign\], multiple sclerosis, Parkinson's disease, Alzheimer's disease or other dementias, Huntington's disease, cerebral aneurysms or arteriovenous malformations \[AVMs\], active central nervous system infections \[e.g., meningitis, encephalitis\], hydrocephalus, other neurodegenerative diseases not otherwise specified, or any other neurological condition that, in the opinion of the principal investigator, may increase risk or interfere with study participation or outcomes)
  • * Metal implants/electronic devices in brain, head, or neck area
  • * Participating in any other clinical trial
  • * History of stroke, brain surgery, tumors, head trauma
  • * Active skin lesions, open wounds, cuts, or infections on the scalp
  • * Active scalp conditions (dermatitis, eczema, psoriasis)
  • * Significant scarring/burns/other skin damage on scalp
  • * Schizophrenia or bipolar disorder
  • * History of suicidal behavior or clinically significant self-injurious behavior (e.g., one or more suicide attempts, non-suicidal self-injury \[NSSI\], or other behaviors indicative of intent to harm oneself), as determined by participant self-report
  • * Treatment plan must be stabilized (4 week analgesic/ 6 month+ hormonal contraception, and crucially no new medication changes)
  • * Planning to commence any new treatment during intervention period
  • * Lack of capacity to consent
  • * No menstruation

Ages Eligible for Study

22 Years to 45 Years

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Samphire Group, Inc.,

Nirav Shah, MD, MPH, PRINCIPAL_INVESTIGATOR,

Study Record Dates

2025-12-05